New lung cancer treatment compared to standard chemotherapy

Plain-English translation of NCT07416994 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see if it works better than a standard chemotherapy drug () for people with advanced lung cancer. You would be eligible if you have a specific type of lung cancer with an EGFR mutation and have already tried at least one EGFR-targeted drug and one platinum-based chemotherapy without success. The study will randomly assign you to receive either or to compare how well each treatment works and how safe it is.

For people with this type of lung cancer who have already tried standard treatments, options are limited and outcomes are often not as good as doctors would like. This medication is being tested to see if it offers a better alternative for patients whose cancer has progressed despite previous treatments.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced or spread lung cancer with a specific EGFR genetic mutation (exon 19 deletion or exon 21 L858R)
you have already received at least one EGFR-targeted drug and at least one platinum-based chemotherapy for your cancer
you are in generally good health, able to carry out daily activities with little or no limitation (ECOG score 0–1)
your cancer has at least one measurable tumor that has not been previously treated with radiation

You likely don't qualify if…

you have a different type of lung cancer, such as small cell lung cancer or squamous cell carcinoma
you have had any other cancer within the past 5 years
you have a history of interstitial lung disease or current lung inflammation
you are pregnant or breastfeeding
you have previously received certain other targeted therapies, including HER3-targeted drugs or topoisomerase I inhibitors

What participation looks like

If you qualify and enroll, you will be randomly assigned to receive either or standard chemotherapy (). You will have regular clinic visits to receive your medication, have blood tests, imaging scans to check how your cancer is responding, and assess any side effects. The study will track how well the medication works and how safe it is compared to the standard treatment over the course of the trial.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Trial locations(2 sites)

China

Shanghai Dongfang Hospital, Shanghai, Shanghai Municipality

Zhejiang Provincial Cancer, Hangzhou, Zhejiang